Drug Trial Radar · NCT03786081
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
214
Actual
Start
Feb 27, 2019
Primary completion
Mar 19, 2026
Study completion Mar 19, 2026
Sponsor
- Lead sponsor
- Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Genmab; European Network of Gynaecological Oncological Trial Groups (ENGOT); Belgian Gynaecological Oncology Group; GOG Foundation; Merck Sharp & Dohme LLC
- First posted
- Dec 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer. The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.
Conditions
- Cervical Cancer
Interventions
Tisotumab VedotinDrug
Given into the vein (IV)
BevacizumabDrug
Given via IV
PembrolizumabDrug
Given via IV
CarboplatinDrug
Given via IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose escalation: Dose Limiting Toxicities (DLTs)Time frame: DLTs will be identified during the first treatment cycle (21 day cycles)
- Dose expansion: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)Time frame: approximately 2 years
Locations
71 sites in 10 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates
Phoenix, Arizona
Univ California, Irvine Medical Center
Orange, California
Olive View - UCLA Research and Education Institute
Sylmar, California
Baptist MD Anderson Cancer Center
Jacksonville, Florida
Augusta University
Augusta, Georgia
University of Chicago
Chicago, Illinois
Indiana University School of Medicine
Indianapolis, Indiana
University of Kansas Medical Center
Westwood, Kansas
Oschner Clinic
New Orleans, Louisiana
Dana-Farber Cancer Institute
Boston, Massachusetts
Billings Clinic Cancer Center
Billings, Montana
Montana Cancer Consortium
Billings, Montana
SUNY Downstate Medical Center
Brooklyn, New York
Memorial Sloan Kettering Cancer Center
New York, New York
University of North Carolina Chapel Hill
Chapel Hill, North Carolina
University of Cincinnati Physicians Group
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
Ohio State University Wexner Medical Center
Hilliard, Ohio
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania
Brown University - Women's and Infant Hospital
Providence, Rhode Island
St Francis Hospital Cancer Center
Greenville, South Carolina
Huntsman Cancer Center
Salt Lake City, Utah
Carilion Clinic
Roanoke, Virginia
AZ Sint-Jan
Bruges, Belgium
Cliniques universitaires Saint-Luc
Brussels, Belgium
Grand Hôpital de Charleroi
Charleroi, Belgium
Universitair Ziekenhuis Antwerpen (UZA)
Edegem, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Universitaire Ziekenhuizen Leuven,
Leuven, Belgium
Centre Hospitalier de l'Ardenne
Libramont, Belgium
Centre Hospitalier Universitaire (CHU) de Liège
Liège, Belgium
Grand Hôpital de Charleroi
Loverval, Belgium
CHU UCL Namur
Namur, Belgium
Sainte-Elisabeth
Namur, Belgium
Fakultni nemocnice Olomouc
Olomouc, Czechia
Fakultni nemocnice Olomouc
Olomouc, Czechia
Fakultni nemocnice Ostrava
Ostrava-Poruba, Czechia
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.